progress human tumour immunology immunotherapy 
studies administration interleukin patients metastatic melanoma kidney cancer shown immunological manipulations can mediate durable regression metastatic cancer molecular identification cancer antigens opened new possibilities development effective immunotherapies patients cancer clinical studies using immunization peptides derived cancer antigens shown high levels lymphocytes anti-tumour activity can raised cancer-bearing patients highly avid anti-tumour lymphocytes can isolated immunized patients grown vitro use cell-transfer therapies current studies aimed understanding mechanisms enable cancer escape immune attack 
